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The current clinical use of psychotropic drugs is trans-
nosologically oriented. This is facilitated by the cur-
rent classification of mental disorders (International
Classification of Diseases, 10th Revision [ICD-10]) and
is perhaps justified if depression and psychosis (taken
here as examples) are considered as being complex
syndromes with heterogeneous etiologies, but com-
mon pathogenesis, more than specific entities.
However, this approach does not identify possible 
differences between specific psychiatric entities,
which could in turn mask differences in therapeutic
responses and, therefore, therapeutic outcome. This is
compounded by the current disharmony between the
nosological classification of diseases, drug develop-
ment, clinical research, and therapeutic uses of psy-
chotropic drugs. Functional pharmacology targeting
abnormal behavioral traits could represent an avenue
for future research and treatment.
he nosological prescription of a drug refers to
the effects of a substance on a specific pathological
entity.The currently used diagnostic classification sys-
tems (Diagnostic and Statistical Manual of Mental Dis-
orders, Fourth Edition [DSM-IV], as well as the Inter-
national Classification of Diseases, 10th Revision
[ICD-10]) are claimed to be “atheoretical,” neglecting
the etiology and pathophysiology of psychiatric disor-
ders.
1 In actual “naturalistic”clinical practice,drugs are
prescribed for a variety of psychopathological condi-
tions that are not necessarily related to nosological cat-
egories.
2 The syndromal heterogeneity of the diagnos-
tic constructs makes it impossible to demonstrate a
potential syndromal specificity of a drug.
Historically,drugs have been developed empirically on
the basis of clinical observations. The discovery of
chlorpromazine for the treatment of schizophrenia in
the early fifties by Delay and Deniker,
3 and of
imipramine for depression a few years later by Kuhn
4
are such examples. On the other hand, new psy-
chopathological syndromes have been identified by
observant clinicians who recognized the unique actions
of psychotropic drugs like clomipramine for the treat-
ment of specific disorders such as obsessive-compulsive
disorder (OCD)
5 or imipramine for panic disorders.
6,7
Unlike other medical conditions,the etiology and patho-
physiology of psychiatric disorders remain unknown.This
is true despite the recent advances in the understanding of
the function of the central nervous system (CNS) and in
the field of biological psychiatry.Neurotransmitter imbal-
ances in some areas of the CNS as well as neuroanatomi-
cal and neurophysiological abnormalities have been
hypothesized to explain most of these psychiatric disor-
ders, but this hypothesis has failed to be conclusively
demonstrated.However,as no rational alternative expla-
nation has been advanced for these disorders,the current
pharmacological approach to the treatment of psychiatric
disorders is based on trying to restore the observed dys-
function of central neurotransmitters.
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Manfred ACKENHEIL Since the ICD-10 and DSM-IV classifications are based
on clinical descriptions, they neglect biochemical and
physiological abnormalities that are involved in the
pathogenesis of disorders.The increasing knowledge of
transmitter function in relation to behavioral pharma-
cology has suggested links to numerous psychiatric con-
ditions.This “pathophysiological approach”to the devel-
opment of new treatments is oriented more toward
behavioral abnormalities than toward nosological syn-
dromes.Pathophysiological approaches allow transnoso-
logical treatment because particular symptoms can occur
in many different psychiatric disorders.
Behavioral abnormalities can be attributed to increased
or decreased neuronal activity, and sometimes to alter-
ations of specific transmitter receptors.This points to a
role for functional pharmacology, which implies that,
rather than nosological categories,one should treat basic
disturbances in cognitive functions,impulse control,per-
ception,information processing,and mood regulation.
Since in many cases monotherapy is insufficient to ade-
quately treat the different nosological categories, natu-
ralistic clinical practice requires that most patients be
treated according to their symptoms with more than one
drug.
2The need for such multiple-drug therapy is due to
many factors, such as multiple syndromes, comorbidity,
and different target symptoms like negative and positive
symptoms in schizophrenia.Frequently,comedication is
prescribed without any pharmacological rationale.
8
Because of pharmacokinetic and pharmacodynamic
interactions (potentiation or diminution), severe side
effects may be induced or be the reason for absence of
response.Better understanding of the principles of clin-
ical pharmacology and education in clinical pharmacol-
ogy are thus major tasks for the future.
The current prescription of psychotropic drugs appears
to be well codified for most of the different ICD-10 cat-
egories (Table I).
Clinical treatment with antidepressants
Drugs for the treatment of affective disorders were dis-
covered by serendipity. Imipramine was found to
improve mood while being used in a protocol to search
for an antipsychotic.
4 Iproniazid, a drug used in the
treatment of tuberculosis, was likewise found to have
beneficial effects on mood.
9The former,a tricyclic anti-
depressant (TCA),and the latter,a monoamine oxidase
inhibitor (MAOI),belong to two classes of drugs still in
use today.
Depressive mood appears to be attributable to dimin-
ished activity of the dopaminergic, noradrenergic, and
serotonergic neurotransmitter systems.Antidepressants
restore the activity of these transmitters by inhibiting
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Selected abbreviations and acronyms
GABA  -aminobutyric acid
5-HT 5-hydroxytryptamine = serotonin
MAO monoamine oxidase 
MAOI monoamine oxidase inhibitor
OCD obsessive-compulsive disorder
SSRI selective serotonin reuptake inhibitor
TCA tricyclic antidepressant
Treatment with
ICD-10 categories AD NL BZD
Organic, including symptomatic, mental disorders + + +
Mental and behavioral disorders due to psychoactive substance use + +
Schizophrenia, schizotypic, and delusional disorders + +++ (+)
Affective disorders +++ + +
Neurotic, stress-related, and somatoform disorders + ++
Behavioral syndromes associated with physiological disturbances and physical factors + +
Abnormalities of adult personality and behavior (+) (+)
Table I. The transnological prescription of antidepressants (AD), neuroleptics (NL), and benzodiazepines (BZD) according to ICD-10
categories (Section V). 177
reuptake in the presynaptic neurons.Additionally, the
classic antidepressants have effects on other neurons (eg,
histamine, acetylcholine), resulting in major side effects
limiting their broader use. Depressive symptoms have
been described in as many as 40 different disorders,which
would imply that they could be used in all of them.
10
Although the efficacy of TCAs has been well estab-
lished, the high incidence of side effects and the high
number of nonresponders or treatment-resistant
patients represent drawbacks that have made it neces-
sary to search for new drugs.The development of selec-
tive serotonin reuptake inhibitors (SSRIs) was the first
attempt based on a pathophysiological approach.These
drugs, which have similar efficacy, but less side effects
than the TCAs, have become the preferred pharmaco-
logical treatment for depression. However, the high
number of nonresponders and the delay in onset of
response have limited their value. Some studies claim
that they are less effective than TCAs in severe depres-
sion.
11 Therefore, antidepressants with dual action have
been developed.Today, up to seven different classes of
antidepressants are available, which mainly differ in
their selectivity for the respective monoamines and their
receptors.
12
These discoveries have intensively stimulated biochem-
ical-pharmacological research into the mechanism of
action of antidepressants. Findings from these investi-
gations suggest that enhanced activity of the central
noradrenergic and/or serotonergic transmitter system is
essential for the clinical antidepressant action. Such
enhancement could be achieved either presynaptically
by blocking  2-adrenergic receptors, or in the synaptic
cleft by inhibiting the transmitter reuptake or the main
metabolic enzyme monoamine oxidase (MAO). The
increased transmitter concentration in the synaptic cleft
after chronic treatment leads to a downregulation of
postsynaptic  -receptors, sometimes modulated by
interaction with neuropeptides and hormones.
13,14
In addition, depending on the antidepressant used, the
sensitivity of 5-HT2A,somatodendritic 5-HT1A,or nora-
drenergic  1 receptors may be reduced, leading to an
overall increase in serotonin transmission. Such recep-
tor alterations appear to provide the best explanation
for the delay in clinical antidepressant response.The
introduction of new classes of antidepressants has led to
renewed thinking about their mechanism of action.
Recent investigations of second messenger systems such
as the adenylate cyclase system and the phosphatidyl-
inositol system are very promising. Antidepressant
drugs,including the mood stabilizers lithium and carbam-
azepine, modulate both of these second messenger sys-
tems,which in turn modulate the phosphorylation status
of neuronal proteins via protein kinase.The outcome is
a positive alteration of the gene expression of the rele-
vant biochemical structures (enzymes, transporters,
receptors), thus restoring the normal function of the
respective neuronal systems.
Thanks to clearer understanding of the function of this
complex serotonergic system we now know that a great
number of normal and abnormal behaviors can be
attributed to dysfunction of the serotonergic neurons,in
addition to their role in depression.The limited number
of serotonin neurons in the brain (approximately 
300 000) suggests that their role is mainly a modulating
one.This implies that they act to either dampen or accel-
erate a given type of behavior.Drugs targeting the sero-
tonergic system are therefore able to influence many
kinds of behavior abnormalities (Figure 1).
Concerning the norepinephrine system,there have been
attempts to link noradrenergic dysfunction to subgroups
of depression.As already mentioned, some forms of
depression are assumed to be accompanied by reduced
noradrenergic activity.However,this is a matter for dis-
cussion, and some forms of depression may even be
accompanied by increased noradrenergic function. It is
hypothesized that noradrenergic neurons in the locus
ceruleus are activated or increased in anxiety and panic
disorders. Conversely, a norepinephrine deficit is
invoked to explain disturbances of attention, psy-
chomotor retardation,and impaired vigilance.
Some antidepressants also increase dopaminergic neu-
ron activity, either directly or indirectly, by acting on
serotonergic and noradrenergic pathways.Dopamine,a
major transmitter of the reward system also plays a role
in depressive states. Dopaminergic antidepressants
could be of interest in some subgroups of depression,
but so far no such drugs are available in Europe. How-
ever, in some patients with refractory depression,
dopaminergic drugs like amphetamine have some ben-
eficial effects.
15
It is difficult to link the three monoaminergic systems to
specific psychiatric disorders.The three systems do not
function independently of each other.Neuronal circuits
establish functional relationships between serotonergic,
noradrenergic, and dopaminergic systems, which
explains why deficiency in one system impairs the other
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SSRIs are also able to modulate the other systems.
The variety of the clinical uses for the newer antide-
pressants may necessitate a reexamination of tradition-
al diagnostic categories and of theories on the way anti-
depressants work.
Antidepressant drugs are used in a wide range of psy-
chiatric disorders. Empirical evidence in the 70s sug-
gested that the nonselective serotonin antidepressant
clomipramine improved symptoms of OCD.
5 Newer
generations of antidepressants with fewer side effects
have proved to be even more active in OCD.
16,17 Fur-
thermore, 5-HT1A serotonin agonists are being investi-
gated in general anxiety disorders.
18 5-HT2 receptor
antagonists are being tested on schizophrenic symptoms,
anxiety, or dysthymia.
19 Other potential indications for
SSRIs and the new generation of antidepressants are
panic disorders,premenstrual dysphoric disorder,eating
disorders, substance abuse disorder, chronic pain,
dementia, and personality disorders with aggression or
impulse disturbances,and general anxiety disorders.
20
Depressive symptoms are frequently diagnosed in
patients with schizophrenia and have been described in
schizoaffective disorders.They can also occur after the
acute phase of schizophrenia or after neuroleptic treat-
ment. SSRIs seem to be useful in combination with
antipsychotics to treat this condition.
20 This may be the
reason why such patients are frequently (50% of cases)
treated simultaneously with antipsychotics and antide-
pressants.
2
Antidepressants are also useful in the treatment of a
group of disorders that may be phenomenologically and
genetically related to major depression, such as
fibromyalgia,chronic fatigue syndrome,migraine,irrita-
ble bowel syndrome, atypical facial pain, and premen-
strual dysphoric disorder.
21 It is likely that the etiology
of depression (as a symptom) in these disorders is simi-
lar to that of major depression as an entity, and there-
fore would explain the efficacy of SSRIs.Although not
impossible, it would be contrary to expectation if the
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Figure 1. Serotonergic receptors, behaviors, and psychiatric disturbances. After G. Fillion, with permission (ubpublished data).mechanism of antidepressant effect was independent of
the mechanism of depression in migraine,premenstrual
dysphoric disorder, and other conditions.And it would
be even more difficult to believe that different, chemi-
cally unrelated antidepressant drugs, share the same
pharmacological properties while having different
mechanisms of action.
12 
Treatment of schizophrenia and other
psychiatric disorders with antipsychotics
Genetic and biological studies show that schizophrenia
is a heterogeneous disease.Disturbances in neurodevel-
opment and/or abnormal immune function may be
responsible for schizophrenic symptoms.
22Additionally,
abnormal dopamine, norepinephrine, and serotonin
transmitter activities in some areas of the brain may be
pathophysiologically relevant to some schizophrenic
syndromes. Other theories put forward disturbances in
the glutamatergic and GABAergic circuits. Because of
this heterogeneity and the impossibility of characteriz-
ing clinical subgroups of schizophrenic patients,none of
these theories has been conclusively proved so far.
23,24
The discovery of chlorpromazine
3 for the treatment of
schizophrenia opened new perspectives for the care of
psychiatric patients. Unfortunately, chlorpromazine and
the other classic neuroleptics produce side effects that
limit their widespread use.For many years,the dopamine
hypothesis, based on the assumed mechanism of action
of these compounds,was the predominant theory.
23
The introduction of new atypical neuroleptics such as
clozapine, which was the first one, paved the way for
revisiting the dopamine hypothesis of schizophrenia and
related theories on the mechanism of action of neu-
roleptics.To explain the unique features of clozapine,
new theories have been put forward, partly in relation
to interference with dopamine receptor subtypes and
partly in relation to interference with other neurotrans-
mitters such as norepinephrine and serotonin.
25 The
nonspecificity of second-generation atypical neurolep-
tics for the dopaminergic system, the therapeutic inef-
fectiveness of some selective dopaminergic drugs, the
lack of success of genetic studies targeted to the
dopaminergic system, and the disappointing biochemi-
cal findings in schizophrenic patients have resulted in
alternative theories of pathogenic causes of schizophre-
nia being proposed,opening up new perspectives for the
development of future drugs. Based on neuropatholog-
ical and neuroanatomical findings and in concordance
with the revised dopamine hypothesis,new models have
been postulated focusing attention on the excitatory
amino acid  -aminobutyric acid (GABA) and the most
ubiquitous amino acid transmitter in the brain, gluta-
mate.
26
Psychotic symptoms of schizophrenia have been divid-
ed into negative symptoms (blunted affect, anhedonia,
asociality, inability to initiate and carry out complex
tasks to completion),which seem to be related to corti-
cal hypofunction, and which, in turn, may be associated
with decreased mesocortical dopaminergic activity and
positive symptoms (hallucinations, delusions, and
thought disorders).They also appear in disorders other
than schizophrenia as well as many nonpsychotic disor-
ders,and are related to increased activity of the subcor-
tical striatal dopaminergic neurons.
Antipsychotic drugs are used in many psychiatric disor-
ders other than schizophrenia. Before lithium was con-
sidered as the standard treatment for bipolar depressive
and manic patients,
27 the pharmacological strategies for
bipolar disorder included neuroleptics and antidepres-
sants.They are now mainly used to treat the psychotic
symptoms present during one of the poles of the disor-
der, or as an adjunctive treatment when other alterna-
tives have failed.There have been several reports that
clozapine may be more effective in patients with mania
and schizoaffective disorder than in patients with schizo-
phrenia. Refractory rapid-cycling and dysphoric mania
also seem to improve with clozapine.Both psychotic and
mood symptoms respond well to clozapine monothera-
py.
28 Preliminary reports suggest that the newer atypical
antipsychotics olanzapine
29 and sertindole may also be
effective in stabilizing mood or in the management of
affective symptoms.
Refractory psychotic depression has also been success-
fully treated with clozapine monotherapy.
28
The occurrence of psychotic symptoms is frequent during
the evolution of idiopathic Parkinson’s disease and other
parkinsonian syndromes. They seem to be related to
interactions between the underlying neuropathological
manifestations of the syndromes and the adverse effects
associated with chronic antiparkinsonian drug adminis-
tration. In patients with advanced Parkinson’s disease,
there is also a high prevalence of affective comorbidity.
Classic neuroleptics may improve the symptoms,but usu-
ally worsen the parkinsonism. Clozapine has been used
successfully since 1985 with only few extrapyramidal
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effects.
30 Olanzapine has been reported to be effective in
the suppression of psychotic symptoms in these patients,
but the currently available dose increments may result in
an exacerbation of motor disability.
31
Transnosological use of psychotropics:
drug development and clinical research
As mentioned above, since no solid alternatives have
emerged from biological research to replace the current
hypothesis regarding the pathogenesis of psychiatric dis-
orders, the development of new psychotropic drugs
remains based on the restoration of the imbalance in the
monoaminergic system.
This is exemplified by the development of the new anti-
depressants.The postulate that depression results from
a dysfunction in the noradrenergic, serotonergic, and
dopaminergic systems leads logically to the attempt to
design antidepressants that act mainly on one of the
neurotransmitter systems.The idea is to increase selec-
tivity without compromising efficacy, while at the same
time reducing the side effects that result of interactions
with these and other neurotransmitter systems.Thus,
blockade of serotonin reuptake gave rise to the now
well-known SSRIs.A new class of drugs, which selec-
tively inhibit the reuptake of norepinephrine, was
recently introduced onto the market. However, experi-
ence with psychotropic drugs acting on either the nor-
adrenergic or the serotonergic systems suggest how
important it is (at least in certain situations) to act on
both systems at once.Research was therefore undertak-
en to develop new antidepressants with a dual action on
these systems.This functional pharmacological approach
focuses on symptoms rather than nosology.
32,33
Conclusion
Although drug development tries to focus on specific
mechanisms involved in depression and its symptoms,
clinical research is not nosologically but transnosologi-
cally oriented.The tools used to monitor therapeutic
response in clinical trials are usually rating scales that
evaluate the depressive or psychotic state rather than
treatment efficacy on a specific entity.Efficacy,nosology,
and duration of treatment are based on the antidepres-
sant effect,and,therefore,in many of the specific entities
where they are presently used, these variables have not
been confirmed.Similarly,in most trials focusing on ther-
apeutic outcome, there are no differences between dif-
ferent drugs belonging to the same therapeutic group.
The current situation is therefore characterized by
disharmony prevailing between psychotropic drug devel-
opment, nosological classification of diseases, clinical
research,and therapeutic uses of psychotropic drugs. ❏181
Prescripción de carácter transnosológico
de los psicofármacos
El uso actual de los psicofármacos tiene una orientación
transnosológica.Esto está favorecido por la actual clasi-
ficación de los trastornos mentales (Clasificación Inter-
nacional de Enfermedades, décima versión [CIE 10]) y
se justifica si la depresión y las psicosis (tomadas aquí
como ejemplos) son consideradas complejos sin-
dromáticos con una etiología heterogénea,pero con una
patogénesis común,más que entidades clínicas específi-
cas.Sin embargo,este enfoque no identifica las posibles
diferencias entre cuadros psiquiátricos específicos,lo que
puede llevar a enmascarar las diferencias en las respues-
tas terapéuticas y por lo tanto, en la evolución del
tratamiento. Esto se complica con la actual disarmonía
entre la clasificación nosológica de las enfermedades,el
desarrollo de medicamentos,la investigación clínica y el
empleo terapéutico de psicofármacos.Una farmacología
funcional orientada a los rasgos de conducta anormal
podría representar un camino para la investigación y 
terapéutica futuras.
L’utilisation thérapeutique
transnosologique des psychotropes
L'utilisation actuelle des psychotropes en pratique
clinique est essentiellement transnosologique. Cette
attitude est favorisée par la classification en vigueur
des maladies mentales (Classification Internationale
des Maladies, 10e édition [ICD-10]), et se justifie sans
doute si l'on considère que la dépression et la psychose
(évoquées dans le présent article) représentent plus des
syndromes complexes, dont les étiologies sont
hétérogènes mais la pathogenèse commune, que des
entités spécifiques. Néanmoins, cette approche ne per-
met pas de différencier les entités psychiatriques spéci-
fiques, ce qui peut conduire à masquer les différences
dans les réponses thérapeutiques et, par conséquent,
dans les résultats obtenus. Ceci est aggravé par le
manque d'harmonisation actuel qui existe entre la
classification nosologique des maladies, le développe-
ment des médicaments, la recherche clinique et les uti-
lisations thérapeutiques des psychotropes.L'approche
ciblée des traits de comportements anormaux par la
pharmacologie fonctionnelle pourrait représenter une
voie d'avenir pour la recherche et la thérapeutique.
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